Pioneering CRISPR-driven solutions for immune and metabolic disorders. Our modular platform accelerates the development of advanced, targeted treatments through rigorous research and clinical collaboration. Backed by leading scientific institutions and industry partnerships.
Harnessing CRISPR and adaptive immunology, our platform enables the creation of targeted cell therapies for complex immune and metabolic conditions, advancing the boundaries of personalized medicine.
Next-generation therapies for rare autoimmune and metabolic diseases through precision engineering and clinical validation.
Our proprietary cell-engineering platform represents a paradigm shift in therapeutic development. By uniting CRISPR precision with adaptive immunology, we address complex immune and metabolic disorders through a modular, scalable approach. Supported by extensive research collaborations, published studies, and a robust clinical pipeline, our platform accelerates the development of targeted, transformative therapies.
Leveraging next-generation CRISPR-Cas systems for precise, multiplexed gene editing with enhanced specificity and reduced off-target effects. Our proprietary editing protocols enable consistent, reproducible cell modifications.
Advanced immune cell reprogramming technologies that restore immune tolerance and modulate inflammatory responses. Our approaches target both adaptive and innate immune systems for comprehensive therapeutic benefit.
GMP-compliant manufacturing processes and quality control systems that ensure reproducible, high-quality cell therapy products. Our scalable platform supports clinical development from Phase 1 through commercialization.
Strategic collaborations with leading academic medical centers, research institutions, and industry partners. Our partnership model accelerates translation from discovery to clinical application.
Our pipeline focuses on high-unmet-need indications where cell therapy can deliver transformative outcomes. We are developing targeted treatments for rare autoimmune diseases and metabolic disorders, with an emphasis on precision, safety, and clinical validation.
Our lead programs target rare autoimmune conditions where current therapeutic options are limited. Through precise immune cell reprogramming, we aim to restore immune tolerance and halt disease progression.
We are exploring applications of our cell-engineering platform for metabolic disorders, where cellular reprogramming offers potential for long-term therapeutic benefit and improved quality of life.
Our research programs are built on a foundation of rigorous scientific inquiry, peer-reviewed publications, and continuous innovation. We maintain active research collaborations with top-tier academic institutions and leverage cutting-edge technologies to advance the field of cell therapy.
Deep understanding of disease pathophysiology and cellular mechanisms enables targeted therapeutic intervention. Our research elucidates the molecular pathways underlying immune and metabolic disorders, informing precision therapeutic design.
Our scientific discoveries are published in leading journals including Nature, Cell, and Science Translational Medicine. Our team actively contributes to the scientific literature, sharing insights that advance the field.
Continuous innovation in gene editing, cell engineering, and manufacturing technologies drives our platform evolution. We invest heavily in R&D to maintain technological leadership and expand therapeutic applications.
Our leadership team combines decades of experience in biotechnology, drug development, and clinical translation. With backgrounds from leading pharmaceutical companies, academic institutions, and regulatory agencies, we bring deep expertise to every aspect of our mission.
Our executive team has a proven track record of advancing innovative therapies from discovery through regulatory approval. Combined experience includes leadership roles at top-tier biotech and pharmaceutical companies, with over 100 years of collective industry experience.
Key Expertise:
Our Scientific Advisory Board comprises distinguished researchers and clinicians from leading academic medical centers. These world-renowned experts provide strategic guidance on research priorities, clinical development, and scientific innovation.
Areas of Expertise:
Our R&D team includes PhD scientists, engineers, and researchers with expertise spanning molecular biology, immunology, bioengineering, and pharmaceutical sciences. Many team members have published extensively in top-tier journals and hold multiple patents.
Team Highlights:
We partner with leading academic institutions, pharmaceutical companies, and research organizations to accelerate therapeutic development. Our collaborative model enables access to cutting-edge research, shared expertise, and expanded clinical capabilities.
We maintain active research collaborations with top-tier academic medical centers and universities. These partnerships provide access to world-class research facilities, clinical expertise, and patient populations, accelerating our drug development programs.
Partnership Focus Areas:
Our industry partnerships enable co-development opportunities, technology licensing, and strategic alliances that accelerate therapeutic advancement. We work with pharmaceutical companies, biotech firms, and technology providers to maximize the impact of our innovations.
Collaboration Models:
We maintain rigorous compliance with FDA regulations, GMP standards, and international regulatory requirements. Our quality systems and regulatory strategy ensure that our therapies meet the highest standards for safety, efficacy, and manufacturing quality.
Celonyx Bio is a biotechnology company dedicated to developing next-generation cell therapies for immune and metabolic disorders. Our mission is to harness the power of precision gene editing and adaptive immunology to create transformative treatments that address unmet clinical needs.
Our team brings together expertise in CRISPR gene editing, immunology, and translational medicine. We maintain the highest standards of scientific rigor in our research and development processes, supported by peer-reviewed publications and industry recognition.
We leverage cutting-edge technologies and novel approaches to solve complex therapeutic challenges. Our modular platform enables rapid development and optimization of cell-based treatments, with continuous innovation driven by our research programs.
Everything we do is guided by our commitment to improving patient outcomes. We prioritize indications with high unmet needs and work tirelessly to advance treatments from bench to bedside, ensuring that our innovations reach those who need them most.
Interested in learning more about our research, exploring collaboration opportunities, or discussing potential partnerships? We welcome inquiries from academic institutions, healthcare organizations, and industry partners.
For general inquiries, partnership opportunities, or media requests:
info@celonyxbio.comWe typically respond within 2-3 business days
Interested in licensing opportunities, co-development partnerships, or strategic collaborations? Contact us to explore how we can work together to advance cell therapy innovation.
Contact Business DevelopmentAcademic institutions and research organizations interested in collaborative research, clinical trials, or technology access are encouraged to reach out. We value scientific partnerships that drive innovation.
Explore Research Partnerships"Collaborating with Celonyx Bio has fundamentally advanced our research in immune cell engineering. Their scientific rigor, innovative CRISPR-based approaches, and transparent communication have enabled us to accelerate the development of targeted therapies for complex autoimmune conditions."
"The team at Celonyx Bio brings exceptional scientific expertise and a collaborative approach to therapeutic development. Their proprietary platform technology has shown significant promise in early studies, and we're excited about the potential to bring these innovative treatments to patients."
Find comprehensive responses to key questions about our cell therapy platform, disease focus, and collaborative research. Learn how our science and partnerships drive innovation in immune and metabolic disorders.
Our therapies utilize a proprietary cell-engineering platform that combines CRISPR-based gene editing with adaptive immunology. This integration enables precise immune cell modification, supporting the development of targeted treatments for complex immune and metabolic conditions.
We focus on indications with high unmet clinical needs, prioritizing rare autoimmune diseases. Our selection process is guided by scientific literature, clinical data, and the potential for significant patient benefit through cellular intervention.
Our modular platform enables rapid adaptation of core cell-engineering technologies to address diverse disease mechanisms. This flexibility accelerates the development of multiple therapeutic candidates across immune and metabolic disorders.
We partner with academic institutions, hospitals, and industry leaders to advance research and clinical development. These collaborations facilitate discovery, validation, and translation of therapies, ensuring scientific rigor and broad clinical reach.
Our approach emphasizes early regulatory engagement, thorough preclinical validation, and adaptive clinical trial designs. This strategy streamlines the transition from discovery to patient access while upholding safety and efficacy.
Organizations interested in collaboration can contact us to discuss research partnerships, co-development, or clinical trial opportunities. We welcome inquiries from those committed to advancing cell-based therapies.